Paula Green Sells 860 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 860 shares of the stock in a transaction on Friday, December 6th. The shares were sold at an average price of $52.70, for a total transaction of $45,322.00. Following the completion of the sale, the senior vice president now directly owns 133,715 shares in the company, valued at approximately $7,046,780.50. This represents a 0.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Paula Green also recently made the following trade(s):

• On Monday, November 11th, Paula Green sold 1,347 shares of Twist Bioscience stock. The shares were sold at an average price of $48.00, for a total transaction of $64,656.00.
• On Wednesday, November 6th, Paula Green sold 5,519 shares of Twist Bioscience stock. The stock was sold at an average price of $44.60, for a total transaction of $246,147.40.
• On Monday, November 4th, Paula Green sold 1,057 shares of Twist Bioscience stock. The shares were sold at an average price of $41.56, for a total value of $43,928.92.
• On Wednesday, October 2nd, Paula Green sold 3,310 shares of Twist Bioscience stock. The shares were sold at an average price of $43.21, for a total value of $143,025.10.
• On Friday, September 20th, Paula Green sold 297 shares of Twist Bioscience stock. The stock was sold at an average price of $46.94, for a total value of $13,941.18.

Twist Bioscience Stock Performance

Twist Bioscience stock traded down $0.09 during mid-day trading on Tuesday, reaching $51.56. 627,617 shares of the company were exchanged, compared to its average volume of 941,410. The firm has a market cap of $3.06 billion, a P/E ratio of -14.35 and a beta of 1.82. The business has a fifty day moving average of $44.49 and a 200 day moving average of $46.51. Twist Bioscience Co. has a 12-month low of $26.51 and a 12-month high of $60.90.

Institutional Investors Weigh In On Twist Bioscience

A number of institutional investors have recently added to or reduced their stakes in the stock. Wilmington Savings Fund Society FSB purchased a new stake in shares of Twist Bioscience during the third quarter valued at about $34,000. Signaturefd LLC raised its stake in shares of Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after acquiring an additional 306 shares in the last quarter. EdgeRock Capital LLC purchased a new stake in Twist Bioscience during the second quarter valued at approximately $43,000. Blue Trust Inc. boosted its stake in Twist Bioscience by 2,912.8% in the second quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock valued at $58,000 after acquiring an additional 1,136 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale purchased a new position in Twist Bioscience in the second quarter worth $61,000.

Analysts Set New Price Targets

TWST has been the topic of a number of research analyst reports. Scotiabank upped their price target on shares of Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a report on Tuesday, November 19th. TD Cowen restated a “buy” rating and issued a $58.00 target price on shares of Twist Bioscience in a research note on Tuesday, November 26th. Leerink Partners lifted their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. Robert W. Baird boosted their price target on Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a report on Tuesday, November 19th. Finally, Evercore ISI raised their price objective on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $51.00.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.